Texto Cientifico

Áñez, G., et al. Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19). Vaccine, 2025 Aug 13, [...]

Zarnegar, B., et al. Matrix-M adjuvant triggers inflammasome activation and enables antigen cross-presentation through induction of lysosomal membrane permeabilization. NPJ Vaccines, 2025 Aug 5, [...]

Pallerla, S., et al. Scale-up and cGMP manufacturing of next-generation vaccine adjuvant Saponin/MPLA NanoParticles (SMNP). J Pharm Sci, 2025 Jul 19, 114(9):103913. PMID: 40692104 This study [...]

Zhou, S.H., et al. Engineered hybrid membrane vesicles combined with autologous and synthetic antigens as therapeutic vaccines to efficiently suppress tumor recurrence. J Control Release, 2025 [...]

Patel, N., et al. Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin-Matrix-M® nanoparticle vaccine induces neutralizing responses in nonhuman primates. Nat Commun, 2025 Jul 18, [...]

Scaria, P.V., et al. SARS-CoV-2 Receptor Binding Domain (RBD) Protein-Protein Conjugate Induces Similar or Better Antibody Responses as Spike mRNA in Rhesus Macaques. Vaccines (Basel), 2025 Jun [...]

Dagnew, A.F., et al. Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 [...]

Caniels, T.G., et al. Precise targeting of HIV broadly neutralizing antibody precursors in humans. Science, 2025 Jul 31, 389(6759):eadv5572. PMID: 40373114 This research focuses on a new HIV [...]

Fergusson, J.R., et al. Ex vivo model of functioning human lymph node reveals role for innate lymphocytes and stroma in response to vaccine adjuvant. Cell Rep, 2025 Jul 22, 44(7):115938. PMID: [...]

Carter, D., et al. The success of toll-like receptor 4 based vaccine adjuvants. Vaccine, 2025 Jun 25, 61:127413. PMID: 40570747 This paper reviews the development and mechanisms of toll-like [...]